Clinical Need in PV
Phlebotomy to maintain Hct at <45%
plus low-dose aspirin
Therapeutic approaches to PV focus on3,11:
• Controlling and maintaining hematocrit levels at <45%
• Treating complications of thrombosis and hemorrhage
• Reducing thrombotic risk and minimizing the risk of
leukogenic transformation
• Managing splenomegaly and other disease-related
symptoms
• Poor compliance or tolerance to
frequent phlebotomy
• Symptomatic or progressive splenomegaly
• High risk of thrombosis
• Severe disease-related symptoms
• Progressive myeloproliferation
(leukocytosis or thrombocytosis)
Phlebotomy is usually the starting point of treatment in patients
with PV, in addition to therapy with low-dose aspirin.2,11 Lowdose aspirin has been shown to prev